SOX17 Mouse Monoclonal Antibody [Clone ID: OTI2F9]
CAT#: TA500045
Sox17 mouse monoclonal antibody, clone OTI2F9 (formerly 2F9)
Size: 30 ul
Formulation: Carrier Free
Specifications
Product Data | |
Clone Name | OTI2F9 |
Applications | FC, WB |
Recommended Dilution | WB 1:5000, IHC 1:50, FLOW 1:100 |
Reactivities | Human, Mouse, Rat |
Host | Mouse |
Isotype | IgG2b |
Clonality | Monoclonal |
Immunogen | Human recombinant protein fragment corresponding to amino acids 177-414 of human SOX17 (NP_071899) produced in E.coli. |
Formulation | PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide. |
Concentration | 0.68 mg/ml |
Purification | Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G) |
Conjugation | Unconjugated |
Storage | Store at -20°C as received. |
Stability | Stable for 12 months from date of receipt. |
Predicted Protein Size | 43.9 kDa |
Gene Name | SRY-box transcription factor 17 |
Database Link | |
Background | SOX17 is a member of the SOX (SRY-related HMG-box) family of transcription factors involved in the regulation of embryonic development and in the determination of the cell fate. It may act as a transcriptional regulator after forming a protein complex with other proteins. |
Synonyms | VUR3 |
Reference Data | |
Protein Families | Transcription Factors |
Protein Pathways | Wnt signaling pathway |
Documents
Product Manuals |
FAQs |
SDS |
Resources
Antibody Resources |
Other Versions
SKU | Description | Size | Price |
---|---|---|---|
CF500045 | Carrier-free (BSA/glycerol-free) Sox17 mouse monoclonal antibody, clone OTI2F9 (formerly 2F9) |
USD 465.00 |
|
TA500045S | Sox17 mouse monoclonal antibody, clone OTI2F9 (formerly 2F9) |
USD 159.00 |
|
TA600123 | SOX17 Capture mouse monoclonal antibody, ELISA and Luminex validated, clone OTI2F9 |
USD 379.00 |
|
TA700123 | SOX17 biotinylated detection antibody, ELISA and Luminex validated mouse monoclonal antibody, clone OTI2F9 |
USD 399.00 |
{0} Product Review(s)
Be the first one to submit a review